213 related articles for article (PubMed ID: 16079263)
1. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5.
Karges B; Krause G; Homoki J; Debatin KM; de Roux N; Karges W
J Endocrinol; 2005 Aug; 186(2):377-85. PubMed ID: 16079263
[TBL] [Abstract][Full Text] [Related]
2. Mutations of the TSH receptor as cause of congenital hyperthyroidism.
Schwab KO; Söhlemann P; Gerlich M; Broecker M; Petrykowski W; Holzapfel HP; Paschke R; Grüters A; Derwahl M
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():124-8. PubMed ID: 8981019
[TBL] [Abstract][Full Text] [Related]
3. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
4. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas.
Castro I; Lima L; Seoane R; Lado-Abeal J
Thyroid; 2009 Jun; 19(6):645-9. PubMed ID: 19499991
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas.
Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G
Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627
[TBL] [Abstract][Full Text] [Related]
6. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism.
Duprez L; Parma J; Van Sande J; Allgeier A; Leclère J; Schvartz C; Delisle MJ; Decoulx M; Orgiazzi J; Dumont J
Nat Genet; 1994 Jul; 7(3):396-401. PubMed ID: 7920658
[TBL] [Abstract][Full Text] [Related]
7. [From gene to disease; thyroid stimulating hormone receptor, hyperthyroidism and hypothyroidism].
Wiersinga WM
Ned Tijdschr Geneeskd; 2001 May; 145(18):869-71. PubMed ID: 11379397
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas.
Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E
Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968
[TBL] [Abstract][Full Text] [Related]
9. Pathology of the TSH receptor.
Duprez L; Parma J; Van Sande J; Rodien P; Sabine C; Abramowicz M; Dumont JE; Vassart G
J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():295-302. PubMed ID: 10698593
[TBL] [Abstract][Full Text] [Related]
10. Mutations of thyrotropin receptor isolated from thyroid autonomous functioning adenomas confer TSH-independent growth to thyroid cells.
Porcellini A; Ruggiano G; Pannain S; Ciullo I; Amabile G; Fenzi G; Avvedimento EV
Oncogene; 1997 Aug; 15(7):781-9. PubMed ID: 9266964
[TBL] [Abstract][Full Text] [Related]
11. Constitutively activating mutations of the thyrotropin receptor and thyroid disease.
Führer D; Holzapfel HP; Wonerow P; Paschke R
Eur J Med Res; 1996 Jul; 1(10):460-4. PubMed ID: 9438142
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades.
Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G
Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518
[TBL] [Abstract][Full Text] [Related]
13. Lack of in vitro constitutive activity for four previously reported TSH receptor mutations identified in patients with nonautoimmune hyperthyroidism and hot thyroid carcinomas.
Jaeschke H; Mueller S; Eszlinger M; Paschke R
Clin Endocrinol (Oxf); 2010 Dec; 73(6):815-20. PubMed ID: 20846293
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous distribution of thyrotrophin receptor messenger ribonucleic acid (TSH-R mRNA) in papillary thyroid carcinomas detected by in situ hybridization.
Tanaka K; Inoue H; Miki H; Komaki K; Monden Y
Clin Endocrinol (Oxf); 1996 Mar; 44(3):259-67. PubMed ID: 8729520
[TBL] [Abstract][Full Text] [Related]
15. [Mutations in the thyrotropin receptor gene in the pathogenesis of toxic thyroid adenomas, toxic goiter nodules and autosomal dominant hyperthyroidism].
Derwahl M
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():25-8. PubMed ID: 10355046
[TBL] [Abstract][Full Text] [Related]
16. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma.
Tonacchera M; Chiovato L; Pinchera A; Agretti P; Fiore E; Cetani F; Rocchi R; Viacava P; Miccoli P; Vitti P
J Clin Endocrinol Metab; 1998 Feb; 83(2):492-8. PubMed ID: 9467563
[TBL] [Abstract][Full Text] [Related]
17. [Non-autoimmune hyperthyroidism and hyperfunctioning thyroid adenomas caused by activating mutation of the thyrotropin receptor].
Kosugi S
Nihon Rinsho; 2002 Feb; 60(2):291-6. PubMed ID: 11857916
[TBL] [Abstract][Full Text] [Related]
18. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the extracellular domain of the thyrotropin receptor.
Kopp P; Muirhead S; Jourdain N; Gu WX; Jameson JL; Rodd C
J Clin Invest; 1997 Sep; 100(6):1634-9. PubMed ID: 9294132
[TBL] [Abstract][Full Text] [Related]
19. Identification of TSH receptor mutations in three families with resistance to TSH.
Tonacchera M; Di Cosmo C; De Marco G; Agretti P; Banco M; Perri A; Gianetti E; Montanelli L; Vitti P; Pinchera A
Clin Endocrinol (Oxf); 2007 Nov; 67(5):712-8. PubMed ID: 17697008
[TBL] [Abstract][Full Text] [Related]
20. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid.
Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G
J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
